A recent study published in Ophthalmology reveals that the combination of polihexanide (PHMB) and propamidine is a safe and effective treatment for the rare eye infection Acanthamoeba keratitis (AK). The research, conducted by John K.G. Dart, D.M., from Moorfields Eye Hospital in London, compared two treatment options for AK involving different concentrations of PHMB. The study included 127 patients.

The findings showed that both treatment groups had similar outcomes. The adjusted medical cure rate within 12 months was 86.6 percent for PHMB 0.02 percent + propamidine and 86.7 percent for PHMB 0.08 percent. These results met the noninferiority requirement for PHMB 0.08 percent. Additionally, both groups had a median best-corrected visual acuity of 20/20 and an overall treatment failure rate of 13.4 percent, with 6.3 percent requiring therapeutic keratoplasty. Importantly, no serious drug-related adverse events were reported.

Dart expressed hope that these robust findings with polihexanide 0.08 percent will revolutionize AK treatment by improving access and consistency, addressing the current unmet needs of patients. It is worth noting that several authors involved in the study disclosed ties to pharmaceutical companies, including SIFI S.p.A., which sponsored and funded the trial.

For more information, you can read the abstract and full text of the study [here](https://www.aaojournal.org/article/S0161-6420(23)00710-8/fulltext).

© 2023 HealthDay. All rights reserved.

Categorized in: